Grant: Operating Grant
McGill University
$311,438.00
Novel unimolecular combination models for selective tumour targeting: A tandem approach to the enhancement of chemoselectivity and abrogation of chemoresistance
EF 2012-13
Résumé
Cancer cells are protected by several proteins that prevent them from dying. These proteins allow them to communicate with the body and particularly to receive message telling them to multiply. Cells that are normal, receive a message to stop multiplying when their job for the body is over. However many cancer cells do not have this stop signal and continue to grow unnecessarily. One class of protein responsible for this behaviour is called "growth factor receptor". In some cancer cells these growth factor receptors are at high levels and most of the time, they do not need to receive a message from the body to tell the cancer cell to divide and more importantly when they feel that the cancer cells are exposed to cancer drugs they launch a message to activate and recruit other proteins that can shield them against the action of anticancer drugs. Therefore these growth factor receptors can not only unnecessarily activate the cancer cells to multiply but also to defend themselves against cancer drugs. Despite the common knowledge that the defence against anticancer drugs is mediated by several proteins, cancer drug researchers persist in making drugs that can block one protein and these drug are classified as "single-targeted". The purpose of the current proposal is to make molecules that are multi-targeted and can hit the cells at several of these shielding proteins in order to make them more sensitive to cancer drugs and ultimately stop the proliferation of cancer cells. We will engineer molecules according to a "divide-and-conquer" trategy whereby these agents will penetrate the cells as a single molecule that will be allowed to degrade into several pieces, each of them being targeted to one of the disordered proteins. This strategy will lead to more efficacious anticancer drugs and is now called "combitargeting".
Programme
Operating Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
281400
Name
Jean-Claude Bertrand J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Novel unimolecular combination models for selective tumour targeting: A tandem approach to the enhancement of chemoselectivity and abrogation of chemoresistance
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$311,438
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Breast; Egf; Egfr; Her1; Her2; Ovarian
Abstract
Cancer cells are protected by several proteins that prevent them from dying. These proteins allow them to communicate with the body and particularly to receive message telling them to multiply. Cells that are normal, receive a message to stop multiplying when their job for the body is over. However many cancer cells do not have this stop signal and continue to grow unnecessarily. One class of protein responsible for this behaviour is called "growth factor receptor". In some cancer cells these growth factor receptors are at high levels and most of the time, they do not need to receive a message from the body to tell the cancer cell to divide and more importantly when they feel that the cancer cells are exposed to cancer drugs they launch a message to activate and recruit other proteins that can shield them against the action of anticancer drugs. Therefore these growth factor receptors can not only unnecessarily activate the cancer cells to multiply but also to defend themselves against cancer drugs. Despite the common knowledge that the defence against anticancer drugs is mediated by several proteins, cancer drug researchers persist in making drugs that can block one protein and these drug are classified as "single-targeted". The purpose of the current proposal is to make molecules that are multi-targeted and can hit the cells at several of these shielding proteins in order to make them more sensitive to cancer drugs and ultimately stop the proliferation of cancer cells. We will engineer molecules according to a "divide-and-conquer" trategy whereby these agents will penetrate the cells as a single molecule that will be allowed to degrade into several pieces, each of them being targeted to one of the disordered proteins. This strategy will lead to more efficacious anticancer drugs and is now called "combitargeting".
Competitiondate
201303
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Jean-Claude, Bertrand J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $311,438~ $0~